A61K 47/6895
Rescue therapy
Official title: {Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies}
A61K47/6895 (Rescue therapy) appears on 32 US grants and 12 published applications in this corpus.
Search patents in A61K- Granted patents
- 32
- Published applications
- 12
- Assignees
- 13
- Inventors
- 22
- Latest grant
- 26 Sep 2017
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 12 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 5 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Neprilysin inhibitors26 Sep 2017US 9,771,337 B2Theravance Biopharma R&D IP, LLC
- Neprilysin inhibitors22 Nov 2016US 9,499,487 B2Theravance Biopharma R&D IP, LLC
- Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug30 Dec 2008US 7,470,429 B2Immunomedics, Inc.
- Rescue agents for treating botulinum toxin intoxications6 Feb 2007US 7,172,764 B2Allergan, Inc.
- Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules1 Oct 2002US 6,458,758 B1Synzyme Technologies, Inc.
- Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri23 Mar 2023US 2023/0087871 A1Sanofi
- Neprilysin inhibitors19 Apr 2018US 2018/0105503 A1Theravance Biopharma R&D IP, LLC
- Neprilysin inhibitors30 Mar 2017US 2017/0088526 A1Theravance Biopharma R&D IP, LLC
- Neprilysin inhibitors6 Dec 2012US 2012/0309724 A1Theravance, Inc.
- Methods for reduced renal uptake of protein conjugates17 Aug 2006US 2006/0182683 A1Center for Molecular Medicine and Immunology
Most cited
By later US patents
- Agonist-antagonist combination to reduce the use of nicotine and other drugs177US 5,574,052 A1996
- Agonist-antagonist combination to reduce the use of nicotine and other drugs137US 5,935,975 A1999
- Agonist-antagonist combination to reduce the use of nicotine and other drugs113US 5,316,759 A1994
- Cytotoxic antibody conjugates and a process for preparation thereof90US 5,030,719 ATeijin Limited · 1991
- Agonist-antagonist combination to reduce the use of nicotine and other drugs35US 5,703,101 A1997